Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 10
1984 16
1985 64
1986 109
1987 41
1988 51
1989 51
1990 58
1991 69
1992 56
1993 57
1994 43
1995 51
1996 47
1997 65
1998 41
1999 50
2000 32
2001 20
2002 34
2003 28
2004 43
2005 38
2006 38
2007 29
2008 29
2009 32
2010 30
2011 30
2012 34
2013 39
2014 25
2015 40
2016 47
2017 32
2018 42
2019 51
2020 81
2021 86
2022 75
2023 67
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

1,837 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF. Titov I, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803. Clin Infect Dis. 2021. PMID: 32785589 Free PMC article. Clinical Trial.
METHODS: This was a randomized, controlled, double-blind phase 3 trial. Adults with HABP/VABP were randomized 1:1 to imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg or piperacillin/tazobactam 4 g/500 mg, intravenously every 6 hours for 7-14 days. ...CONCLUSIONS: Imipen …
METHODS: This was a randomized, controlled, double-blind phase 3 trial. Adults with HABP/VABP were randomized 1:1 to imipenem/cilastatin …
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA. Heo YA. Drugs. 2021 Feb;81(3):377-388. doi: 10.1007/s40265-021-01471-8. Epub 2021 Feb 25. Drugs. 2021. PMID: 33630278 Free PMC article. Review.
Imipenem/cilastatin/relebactam (Recarbrio) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel beta-lactamase inhibitor relebactam. ...It was also effective in imipenem-nonsuscepti …
Imipenem/cilastatin/relebactam (Recarbrio) is an intravenously administered combination of the carbapenem imipenem, the renal dehydro …
Imipenem-cilastatin.
Dinsmoor MJ. Dinsmoor MJ. Obstet Gynecol Clin North Am. 1992 Sep;19(3):475-82. Obstet Gynecol Clin North Am. 1992. PMID: 1436925 Review.
Imipenem-cilastatin, with its broad spectrum of activity and relative safety, offers an excellent alternative for the treatment of many obstetric and gynecologic infections. ...Misuse and overuse of imipenem-cilastatin will result in the further development of resis …
Imipenem-cilastatin, with its broad spectrum of activity and relative safety, offers an excellent alternative for the treatment of ma …
Cilastatin as a protective agent against drug-induced nephrotoxicity: a literature review.
Shayan M, Elyasi S. Shayan M, et al. Expert Opin Drug Saf. 2020 Aug;19(8):999-1010. doi: 10.1080/14740338.2020.1796967. Epub 2020 Jul 23. Expert Opin Drug Saf. 2020. PMID: 32666842 Review.
INTRODUCTION: Cilastatin, a dehydropeptidase I inhibitor, has been used alongside imipenem, a broad spectrum antibiotic, in order to reduce its renal metabolism, consequently increasing its urinary recovery and effectiveness for many years. ...In this review, the authors g …
INTRODUCTION: Cilastatin, a dehydropeptidase I inhibitor, has been used alongside imipenem, a broad spectrum antibiotic, in order to …
Imipenem cilastatin sodium-associated thrombocytopenia in an older patient: A case report and literature review.
Qiao W, Chang C, Wang Q, Cao X, Zhang X. Qiao W, et al. Int J Clin Pharmacol Ther. 2022 Aug;60(8):358-363. doi: 10.5414/CP204215. Int J Clin Pharmacol Ther. 2022. PMID: 35652550 Review.
Thrombocytopenia has been reported as a rare adverse event in several studies of patients treated with imipenem cilastatin sodium. In this study, we present a case of thrombocytopenia associated with imipenem cilastatin sodium in an older patient. The 78-year-old ma …
Thrombocytopenia has been reported as a rare adverse event in several studies of patients treated with imipenem cilastatin sodium. In …
Imipenem-Cilastatin-Relebactam: A Novel beta-Lactam-beta-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR, Rybak JM, Claeys KC. Smith JR, et al. Pharmacotherapy. 2020 Apr;40(4):343-356. doi: 10.1002/phar.2378. Epub 2020 Mar 9. Pharmacotherapy. 2020. PMID: 32060929 Review.
Imipenem-cilastatin-relebactam (IMI-REL) is a novel beta-lactam-beta-lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAIs). ...Available clinical and pharmacokin …
Imipenem-cilastatin-relebactam (IMI-REL) is a novel beta-lactam-beta-lactamase inhibitor combination recently approved for the treatm …
Imipenem/cilastatin/relebactam: A new carbapenem beta-lactamase inhibitor combination.
Mansour H, Ouweini AEL, Chahine EB, Karaoui LR. Mansour H, et al. Am J Health Syst Pharm. 2021 Mar 31;78(8):674-683. doi: 10.1093/ajhp/zxab012. Am J Health Syst Pharm. 2021. PMID: 33580649
The addition of relebactam does not restore the activity of imipenem against metallo-beta-lactamase (MBL)-producing Enterobacterales and carbapenem-resistant Acinetobacter baumannii. Two phase 3 clinical trials of imipenem/cilastatin/relebactam were conducted. In the RESTO …
The addition of relebactam does not restore the activity of imipenem against metallo-beta-lactamase (MBL)-producing Enterobacterales and car …
Carbapenems: past, present, and future.
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Papp-Wallace KM, et al. Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. doi: 10.1128/AAC.00296-11. Epub 2011 Aug 22. Antimicrob Agents Chemother. 2011. PMID: 21859938 Free PMC article. Review.
We also highlight important features of the carbapenems that are presently in clinical use: imipenem-cilastatin, meropenem, ertapenem, doripenem, panipenem-betamipron, and biapenem. ...
We also highlight important features of the carbapenems that are presently in clinical use: imipenem-cilastatin, meropenem, ertapenem …
Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.
Benfield P, Chrisp P. Benfield P, et al. Pharmacoeconomics. 1992 Jun;1(6):443-59. doi: 10.2165/00019053-199201060-00005. Pharmacoeconomics. 1992. PMID: 10147024 Review.
Imipenem/cilastatin possesses a very broad spectrum of antibacterial activity that encompasses the range of Gram-negative and Gram-positive aerobes and anaerobes usually associated with intra-abdominal and other polymicrobial infections. ...The available pharmacoeconomic s …
Imipenem/cilastatin possesses a very broad spectrum of antibacterial activity that encompasses the range of Gram-negative and Gram-po …
1,837 results

Searches related to "cilastatin"